A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with AdvancedA Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors (REFMAL 449) Solid Tumors (REFMAL 449)

Sponsor
Checkpoint Therapeutics, Inc.

Protocol Number
Checkpoint (SCRI) REFMAL 499 CK-101-101

To Learn More Call
201-510-0910